News archive
Showing 765 results
December 2008
-
Media Release
RAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
- RAD001 combined with Herceptin and chemotherapy in two separate Phase I trials halted tumor growth in 77% and 62% of patients, respectively- Novartis to start Phase III clinical trial program to… -
Media Release
RAD001 Shows Potential to Reverse Resistance to Herceptin®* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
November 2008
-
Media Release
Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'
- Partnership aims to provide convenient access to vaccination - helping keep kids and teachers in school and parents at work- "Let's Fight Flu Together!" initiative supports CDC's new vaccination… -
Media Release
Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'
October 2008
-
Media Release
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
-- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH) -- Current treatment options have limited benefit for this debilitating, rapidly progressive and… -
Media Release
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
September 2008
-
Media Release
RAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot- 77% of patients with pancreatic NET… -
Media Release
RAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
-
Media Release
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
-- Regulatory applications to be submitted worldwide for RAD001 first submissions filed in the Hidden List US, EU and Switzerland -- Data showing that RAD001 more than doubles time without tumor… -
Media Release
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
July 2008
-
Media Release
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
Jury verdict in Montgomery County Circuit Court awards $33 million in compensatory damagesJury decides in favor of Novartis and rejects claims for punitive damagesNPC maintains it reported true and… -
Media Release
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case